| Not Yet Recruiting | Dapagliflozin for Long COVID Syndrome NCT06907251 | Ottawa Heart Institute Research Corporation | Phase 3 |
| Recruiting | Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease NCT07224490 | Stephanie B. Seminara, MD | Phase 1 |
| Recruiting | Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID NCT07416539 | Rokote Laboratories Finland Oy | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age W NCT07266558 | ModernaTX, Inc. | Phase 4 |
| Not Yet Recruiting | mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes NCT06919796 | PharmaJet, Inc. | Phase 2 |
| Completed | Secondary Databased Post-marketing Surveillance Study of BNT162b2 NCT06743334 | Pfizer | — |
| Enrolling By Invitation | Neurological Development In Toddlers After Maternal SARS-CoV-2 Infection During Pregnancy NCT06968897 | Philipps University Marburg | — |
| Completed | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Va NCT06864143 | ModernaTX, Inc. | Phase 2 |
| Withdrawn | ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19) NCT05433181 | University of Pennsylvania | Phase 1 / Phase 2 |
| Withdrawn | SARS-CoV-2 Safety Study for the Treatment of COVID-19 NCT06489860 | DHA Coffee Co., Ltd | Phase 2 |
| Completed | MxA-Guided Antiviral Treatment in Respiratory Viral Infections NCT06668025 | Capital Medical University | N/A |
| Completed | Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay NCT06689423 | Credo Diagnostics Biomedical Pte. Ltd. | — |
| Recruiting | Viral Infection of HSPC Impacts Hematopoiesis NCT06458504 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Trea NCT06684379 | PEACHES BIOTECH | Phase 1 / Phase 2 |
| Not Yet Recruiting | Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immun NCT06610643 | National Taiwan University Hospital | N/A |
| Recruiting | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations NCT06585241 | ModernaTX, Inc. | Phase 4 |
| Completed | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 ( NCT06508320 | ModernaTX, Inc. | Phase 2 |
| Completed | A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults NCT06354998 | ModernaTX, Inc. | Phase 3 |
| Completed | Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years NCT06130410 | Pfizer | — |
| Completed | PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19 NCT05954286 | Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 2 |
| Unknown | Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vac NCT06167915 | Guangzhou Patronus Biotech Co., Ltd. | Phase 1 |
| Completed | The Impact of the COVID-19 Pandemic on the Patient in Need of an Intervention NCT05736822 | University Medical Center Groningen | — |
| Active Not Recruiting | Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data NCT05876377 | Pfizer | — |
| Completed | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age NCT06097273 | ModernaTX, Inc. | Phase 3 |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA NCT05939648 | AIM Vaccine Co., Ltd. | Phase 2 |
| Completed | Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data NCT06199934 | Pfizer | — |
| Completed | A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participa NCT06039449 | Invivyd, Inc. | Phase 3 |
| Unknown | A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA NCT05939596 | AIM Vaccine Co., Ltd. | Phase 1 |
| Completed | Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa NCT05938075 | Vaccine Company, Inc. | Phase 1 |
| Unknown | A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine NCT05947812 | 60P Australia Pty Ltd | Phase 2 |
| Completed | A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults NCT05960097 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants NCT07050511 | Generate Biomedicines | Phase 1 |
| Recruiting | Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB) NCT06914635 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Completed | Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States NCT05870839 | Vaccine Company, Inc. | Phase 1 |
| Unknown | Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Re NCT05787444 | LumiraDx UK Limited | — |
| Active Not Recruiting | Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults NCT05799651 | Glycovax Pharma Inc. | Phase 1 |
| Completed | Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran NCT06130345 | ModernaTX, Inc. | — |
| Completed | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults NCT05827926 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Unknown | A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chi NCT05549206 | AIM Vaccine Co., Ltd. | N/A |
| Unknown | Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad NCT05428592 | AIM Vaccine Co., Ltd. | Phase 3 |
| Unknown | Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older NCT05812014 | AIM Vaccine Co., Ltd. | Phase 3 |
| Completed | Addressing Post-COVID-19 Musculoskeletal Symptoms NCT05516836 | Universidad Europea de Madrid | N/A |
| Active Not Recruiting | Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEV NCT06333704 | ModernaTX, Inc. | — |
| Completed | eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services NCT05712096 | AstraZeneca | — |
| Completed | Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of NCT05728970 | LumiraDx UK Limited | — |
| Unknown | Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants NCT05599802 | AIM Vaccine Co., Ltd. | Phase 1 |
| Unknown | A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 NCT05682638 | AIM Vaccine Co., Ltd. | Phase 3 |
| Unknown | Clinical Trial of COVID-19 Vaccine（SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine） in Participants Aged 18 Year NCT05745545 | AIM Vaccine Co., Ltd. | N/A |
| Recruiting | Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads NCT05370014 | University of South Carolina | N/A |
| Completed | Changes of Optical Quality During the Peak of the Covid-19 Pandemic NCT05882383 | Tianjin Eye Hospital | — |
| Completed | Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Res NCT05894525 | ModernaTX, Inc. | — |
| Completed | Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavi NCT05894499 | ModernaTX, Inc. | — |
| Completed | Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV NCT05894590 | ModernaTX, Inc. | — |
| Unknown | Virus and Bronchial Epithelium in Children and the Elderly NCT06224062 | University Hospital, Bordeaux | N/A |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RS NCT05585632 | ModernaTX, Inc. | Phase 1 |
| Active Not Recruiting | Immunity to Infection in Healthy Participants and Participants With Cancer NCT05787964 | University Hospital Tuebingen | — |
| Terminated | Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine NCT05584202 | ModernaTX, Inc. | Phase 2 |
| Unknown | A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China NCT05547243 | AIM Vaccine Co., Ltd. | N/A |
| Unknown | A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged NCT05550142 | AIM Vaccine Co., Ltd. | N/A |
| Unknown | A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Ov NCT05547256 | AIM Vaccine Co., Ltd. | N/A |
| Unknown | The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Age NCT05492643 | Zhongnan Hospital | N/A |
| Completed | Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adult NCT05477186 | GlaxoSmithKline | Phase 1 |
| Terminated | A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated NCT05104840 | Center Trials & Treatment | — |
| Completed | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 NCT05436834 | ModernaTX, Inc. | Phase 3 |
| Unknown | A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults. NCT05354063 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3 NCT05222425 | Biomad AS | Phase 3 |
| Completed | A Study of Modified mRNA Vaccines in Healthy Adults NCT05397223 | ModernaTX, Inc. | Phase 1 |
| Terminated | Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™) NCT05403346 | Lumos Diagnostics | — |
| Completed | Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster NCT05897190 | Argorna Pharmaceuticals Co., LTD | Phase 1 |
| Completed | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 7 NCT05375838 | ModernaTX, Inc. | Phase 1 / Phase 2 |
| Unknown | The Safety and Tolerability of A8G6 COVID-19 Neutralization Antibody Combined With Nasal Spray NCT06127498 | The Second Affiliated Hospital of Chongqing Medical University | N/A |
| Unknown | A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years. NCT05354089 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Completed | Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19 NCT05233826 | Codagenix, Inc | Phase 1 |
| Completed | A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind NCT05367908 | ModernaTX, Inc. | — |
| Completed | Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro- NCT05272605 | University of Melbourne | Phase 1 |
| Completed | Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adu NCT05260437 | GlaxoSmithKline | Phase 1 |
| Completed | AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics NCT05281601 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Korea Comirnaty Post-marketing Surveillance NCT05032976 | Pfizer | — |
| Completed | Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People NCT05352867 | AIM Vaccine Co., Ltd. | Phase 2 |
| Terminated | High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients NCT05280158 | University of California, Los Angeles | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level A NCT05194033 | Peking University | N/A |
| Completed | Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and P NCT05435027 | Gritstone bio, Inc. | Phase 1 |
| Completed | Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level A NCT05195047 | Peking University | N/A |
| Completed | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Boo NCT05249829 | ModernaTX, Inc. | Phase 2 / Phase 3 |
| Completed | A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. NCT05181709 | Sean Liu | Phase 1 |
| Completed | Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX ) NCT05281692 | Convergent Genomics, Inc. | — |
| Unknown | Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease NCT04412395 | National Research Centre, Egypt | Phase 2 |
| Withdrawn | Data Analysis of the Cytokine Adsorption Treatment on Coronavirus Disease-19 (COVID-19) Patients With Respirat NCT04422626 | University of Pecs | — |
| Completed | Study SARS-CoV-2-CZ-PREVAL-II - Arm of the Olomouc Region NCT07387211 | The Institute of Molecular and Translational Medicine, Czech Republic | N/A |
| Completed | Within Household Transmission of COVID-19 Infections NCT05430516 | UMC Utrecht | — |
| Completed | Biomarkers for Post-COVID Conditions NCT05196516 | Zealand University Hospital | — |
| Completed | The Effects of a Music Therapy Respiratory Protocol on Post-Covid-19 Respiratory Symptoms NCT05231512 | Icahn School of Medicine at Mount Sinai | N/A |
| Unknown | Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccin NCT04844268 | SENAI CIMATEC | Phase 1 |
| Completed | A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults NCT05903118 | Argorna Pharmaceuticals Co., LTD | Phase 1 / Phase 2 |
| Completed | Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 NCT05077930 | Tânia Portella Costa | Phase 2 |
| Unknown | Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial NCT04332666 | Erasme University Hospital | Phase 2 / Phase 3 |
| Completed | A Study of S-268019 for the Prevention of COVID-19 NCT05212948 | Shionogi | Phase 3 |
| Unknown | The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects NCT05977101 | The Second Affiliated Hospital of Chongqing Medical University | N/A |
| Withdrawn | Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 NCT05137795 | APR Applied Pharma Research s.a. | Phase 3 |
| Completed | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters NCT05137236 | ModernaTX, Inc. | Phase 2 |
| Unknown | Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnosti NCT04366219 | Centre Hospitalier le Mans | — |
| Unknown | Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COV NCT05876364 | Quratis Inc. | Phase 1 |
| Terminated | COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVI NCT05081388 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community NCT05047900 | Mahidol University | N/A |
| Withdrawn | A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Comp NCT04838847 | CureVac | Phase 3 |
| Withdrawn | The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19 NCT04891250 | Centre for Infectious Disease Research in Zambia | Phase 4 |
| Completed | A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults NCT05366322 | ModernaTX, Inc. | — |
| Withdrawn | Characteristics of Patients With COVID-19 in Meta State, Colombia NCT04456426 | Hospital Departamental de Villavicencio | — |
| Completed | Detecting SARS-CoV-2 in Tears NCT04526769 | University of Minnesota | — |
| Terminated | Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study NCT04958304 | ModernaTX, Inc. | — |
| Completed | COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the Unite NCT05020145 | Pfizer | — |
| Withdrawn | Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System En NCT04854876 | Royal College of Surgeons in Ireland - Medical University of Bahrain | N/A |
| Active Not Recruiting | Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study) NCT04967807 | University Health Network, Toronto | N/A |
| Withdrawn | Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune NCT04498325 | Washington University School of Medicine | Phase 1 |
| Unknown | A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-1 NCT04847102 | Walvax Biotechnology Co., Ltd. | Phase 3 |
| Completed | Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 NCT04958954 | ModernaTX, Inc. | — |
| Unknown | Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVac NCT05084950 | Centre Scientifique de Monaco | — |
| Completed | SARS-CoV-2/COVID-19 Infection Among Health Care Workers NCT04826718 | Universidade de Cabo Verde | — |
| Completed | Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities NCT04901624 | University of Southern California | N/A |
| Completed | Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults NCT04973449 | AstraZeneca | Phase 2 / Phase 3 |
| Withdrawn | Level of Immunity, Neutralization of the COVID-19 Virus and Reinfections in Residents of 2 Migrant Workers' Re NCT04932837 | Epicentre | — |
| Unknown | The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled NCT05007457 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Recruiting | Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19) NCT06775457 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Unknown | Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination NCT05009134 | Huazhong University of Science and Technology | — |
| Completed | National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units NCT04779541 | University Hospital, Angers | — |
| Unknown | EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-1 NCT05059106 | Federal University of Espirito Santo | Phase 2 / Phase 3 |
| Withdrawn | Capturing Infectious COVID-19 Asymptomatic Cases in Singapore NCT04812327 | Becton, Dickinson and Company | — |
| Withdrawn | Emergency Department (ED) Self-Monitoring Pilot COVID-19 NCT04462783 | University of Michigan | N/A |
| Withdrawn | Risk of SARS-CoV-2 Infection (COVID-19) in a Standing Concert in a Closed Performance Hall NCT04896970 | University Hospital, Montpellier | N/A |
| Completed | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants NCT04927065 | ModernaTX, Inc. | Phase 2 / Phase 3 |
| Unknown | Investigation the Effect of Montelukast in COVID-19 NCT04718285 | Bahçeşehir University | Phase 2 |
| Active Not Recruiting | SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination NCT04939402 | Universitair Ziekenhuis Brussel | N/A |
| Completed | Protecting Our Community: COVID-19 Testing NCT04866303 | Montana State University | N/A |
| Terminated | COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV NCT04860258 | CureVac | Phase 3 |
| Completed | A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transpla NCT04860297 | ModernaTX, Inc. | Phase 3 |
| Unknown | Neurological Outcome After SARS-CoV-2 Infection NCT05025839 | Medical University Innsbruck | — |
| Completed | A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults NCT04591184 | Entos Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Withdrawn | Trial to Promote Recovery From COVID-19 With Endocrine Therapy NCT04374279 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations NCT04853004 | Karolinska Institutet | — |
| Terminated | NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons NCT04799392 | NOWDiagnostics, Inc. | N/A |
| Terminated | Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) NCT04409873 | University of California, San Francisco | Phase 2 |
| Not Yet Recruiting | To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 NCT04709328 | Sinocelltech Ltd. | Phase 2 / Phase 3 |
| Unknown | Tolerability and Efficacy of RJX in Patients With COVID-19 NCT04708340 | Reven Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms NCT04854759 | Independent Public Clinical Hospital No. 4 in Lublin | Phase 3 |
| Completed | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Month NCT04796896 | ModernaTX, Inc. | Phase 2 / Phase 3 |
| Completed | Assessment of the Impact of COVID-19 Pandemic on Residents Training and Mental Health in Poland NCT04753463 | Medical University of Bialystok | — |
| Terminated | Convalescent Plasma for Early Treatment of COVID-19 NCT04390503 | Andrew Eisenberger | Phase 2 |
| Completed | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy NCT04813796 | ModernaTX, Inc. | Phase 1 |
| Completed | Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients NCT04414059 | Elsan | — |
| Completed | Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample NCT04654442 | University Hospital, Grenoble | — |
| Unknown | Anti COVID-19 Antibodies in Follicular Fluid and Spermatic Fluid NCT04822012 | Meir Medical Center | — |
| Unknown | Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines NCT05150834 | Korea University Guro Hospital | — |
| Unknown | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay NCT05074745 | Centre Scientifique de Monaco | N/A |
| Completed | Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals NCT04915989 | Genexine, Inc. | Phase 1 |
| Terminated | Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 NCT04360096 | APR Applied Pharma Research s.a. | Phase 2 / Phase 3 |
| Completed | Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™) NCT04750629 | Lumos Diagnostics | — |
| Completed | Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic o NCT04703114 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2 NCT04698837 | Insel Gruppe AG, University Hospital Bern | — |
| Unknown | Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients NCT04717011 | Igenomix | — |
| Withdrawn | A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine NCT04683224 | Vaxxinity, Inc. | Phase 2 / Phase 3 |
| Completed | Asymptomatic SARS-CoV-2 Detection in Children NCT04853316 | University of Calgary | — |
| Terminated | COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19 NCT04703140 | CMC Ambroise Paré | N/A |
| Unknown | COVID-19 Vaccine Induced Adaptive Immune Responses NCT04729374 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Unknown | Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Pat NCT04716985 | AGIR à Dom | N/A |
| Unknown | Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19) NCT04931238 | Peking Union Medical College Hospital | Phase 2 |
| Terminated | Prevalence of SARS-CoV-2 Genome in Tears of Asymptomatic and Moderately Symptomatic COVID-19 Patients NCT04654325 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50 NCT05993143 | Insud Pharma | Phase 3 |
| Withdrawn | Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test NCT04808921 | Sky Medical Supplies & Equipments, LLC | N/A |
| Completed | Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID- NCT04608214 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Unknown | EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2) NCT04335032 | S.L.A. Pharma AG | Phase 3 |
| Terminated | Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 NCT04728347 | Arcturus Therapeutics, Inc. | Phase 2 |
| Completed | The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load NCT04721457 | King Abdulaziz University | Phase 4 |
| Unknown | Fase I Clinical Trial on NK Cells for COVID-19 NCT04634370 | Hospital de Clinicas de Porto Alegre | Phase 1 |
| Completed | GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19) NCT04673149 | GeneOne Life Science, Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults NCT04715997 | Genexine, Inc. | Phase 1 / Phase 2 |
| Terminated | CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2) NCT04627675 | Providence Health & Services | Phase 1 |
| Completed | Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece NCT04700254 | Chania General Hospital "St. George" | — |
| Completed | Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test NCT04689399 | Rigshospitalet, Denmark | N/A |
| Unknown | The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection NCT04664049 | National Research Institute of Chinese Medicine, Ministry of Health and Welfare | — |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 NCT04674189 | CureVac | Phase 3 |
| Completed | A Study of the Effectiveness of Moderna COVID-19 Vaccine NCT05933304 | ModernaTX, Inc. | — |
| Completed | Carrageenan Nasal Spray for COVID-19 Prophylaxis NCT04590365 | Swansea University | N/A |
| Completed | A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Effi NCT04652102 | CureVac | Phase 2 / Phase 3 |
| Completed | Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling NCT04437706 | Duke University | — |
| Completed | Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19. NCT04839094 | Centre Hospitalier Universitaire Vaudois | — |
| Completed | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <1 NCT04649151 | ModernaTX, Inc. | Phase 2 / Phase 3 |
| Completed | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population NCT04649021 | BioNTech SE | Phase 2 |
| Completed | Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19 NCT04592549 | Alachua Government Services, Inc. | Phase 1 |
| Completed | Sero-prevalence COVID-19 Among Belgian Children NCT04613817 | Sciensano | — |
| Completed | Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2 NCT04655521 | Universität des Saarlandes | — |
| Terminated | Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia NCT04619693 | University Hospital, Montpellier | — |
| Completed | Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID NCT04779424 | Universiteit Antwerpen | — |
| Completed | Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID NCT04542850 | Royal College of Surgeons in Ireland - Medical University of Bahrain | N/A |
| Unknown | Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19) NCT04639375 | E-MO Biology Inc | Phase 4 |
| Completed | Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers NCT04619407 | University Medicine Greifswald | — |
| Terminated | Anti-SARS Cov-2 T Cell Infusions for COVID 19 NCT04401410 | Baylor College of Medicine | Phase 1 |
| Unknown | A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 NCT04540185 | Biomed Industries, Inc. | Phase 3 |
| Completed | Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial NCT04472611 | Yale University | Phase 3 |
| Completed | Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients NCT04497389 | University of Utah | Phase 1 / Phase 2 |
| Completed | WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories NCT04357834 | Insel Gruppe AG, University Hospital Bern | — |
| Terminated | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respirato NCT04565249 | Pliant Therapeutics, Inc. | Phase 2 |
| Completed | Prognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2 NCT04672343 | Centre Hospitalier Universitaire Dijon | — |
| Unknown | Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment NCT04918914 | Hunt Regional Medical Center | EARLY_Phase 1 |
| Terminated | Lactoferrin for Prevention of COVID-19 in Health Care Workers NCT04526821 | Universidad Peruana Cayetano Heredia | Phase 2 |
| Terminated | Control of COVID-19 Outbreaks in Long Term Care NCT04448119 | Appili Therapeutics Inc. | Phase 2 |
| Completed | COG-UK Project Hospital-Onset COVID-19 Infections Study NCT04405934 | University College, London | N/A |
| Terminated | Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise NCT04472494 | Bristol-Myers Squibb | Phase 2 |
| Completed | Nasal Photodisinfection COVID-19 Proof of Concept Study NCT04615936 | Sunnybrook Health Sciences Centre | N/A |
| Unknown | Outpatient Treatment With CoVid-19 With Prexablu NCT04619290 | Hospital Reg. Lic. Adolfo Lopez Mateos | Phase 1 |
| Completed | Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) NCT04546581 | University of Minnesota | Phase 3 |
| Completed | PEP Flute-selfcare in COVID-19 NCT04530435 | Bispebjerg Hospital | N/A |
| Completed | COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement NCT04369794 | University of Campinas, Brazil | Phase 4 |
| Terminated | AnaConDa-therapy in COVID-19 Patients NCT05586126 | Jeroen Bosch Ziekenhuis | — |
| Unknown | P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 NCT04410510 | Hospital Universitario San Ignacio | Phase 2 / Phase 3 |
| Completed | Repeat Testing for SARS-CoV-2 NCT04579549 | University of Wisconsin, Madison | N/A |
| Unknown | Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection NCT04747574 | Tel-Aviv Sourasky Medical Center | Phase 1 |
| Completed | PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19) NCT04613310 | Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | N/A |
| Terminated | DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury NCT04447404 | Durect | Phase 2 |
| Completed | A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healt NCT04515147 | CureVac | Phase 2 |
| Completed | Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students NCT04620798 | Indiana University | N/A |
| Completed | Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 NCT04452604 | French Innovative Leukemia Organisation | — |
| Completed | Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population NCT04561102 | Illumina, Inc. | — |
| Completed | FREEDOM COVID-19 Anticoagulation Strategy NCT04512079 | Valentin Fuster | Phase 4 |
| Completed | Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 NCT04527471 | Verona Pharma Inc | Phase 2 |
| Withdrawn | Interferon Lambda Therapy for COVID-19 NCT04388709 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Withdrawn | Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 NCT04386447 | Azienda Ospedaliero-Universitaria di Parma | Phase 2 |
| Suspended | Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation NCT04385771 | Dr. Alexander Supady | N/A |
| Terminated | Cardiovascular Implications of COVID-19 NCT04435457 | University of Texas Southwestern Medical Center | — |
| Completed | NOWDx Test for the Detection of Antibodies to COVID-19 NCT04690413 | NOWDiagnostics, Inc. | N/A |
| Completed | Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults NCT04516746 | AstraZeneca | Phase 3 |
| Completed | Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection NCT04750720 | Centre Hospitalier Régional d'Orléans | N/A |
| Completed | Study of Sargramostim in Patients With COVID-19 NCT04411680 | Partner Therapeutics, Inc. | Phase 2 |
| Completed | Favipiravir vs Hydroxychloroquine vs Control in COVID -19 NCT04387760 | Royal College of Surgeons in Ireland - Medical University of Bahrain | Phase 2 |
| Completed | Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects NCT04480957 | Arcturus Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) NCT04363866 | Oregon Health and Science University | Phase 2 |
| Terminated | TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study) NCT04405271 | Hospital Italiano de Buenos Aires | Phase 3 |
| Completed | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects NCT04523571 | BioNTech SE | Phase 1 |
| Completed | A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Olde NCT04470427 | ModernaTX, Inc. | Phase 3 |
| Completed | SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling NCT04460638 | Direction Centrale du Service de Santé des Armées | — |
| Completed | Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC3) NCT05764083 | VA Office of Research and Development | — |
| Withdrawn | Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota NCT04473183 | University of Minnesota | — |
| Completed | A Study of Immune Responses to the Virus That Causes COVID-19 NCT04431414 | COVID-19 Prevention Network | — |
| Completed | Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19) NCT04473365 | Mekelle University | — |
| Terminated | Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Impr NCT04433546 | PhaseBio Pharmaceuticals Inc. | Phase 2 |
| Completed | Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVI NCT04447781 | International Vaccine Institute | Phase 1 / Phase 2 |
| Withdrawn | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial) NCT04456088 | Beyond Air Inc. | Phase 2 |
| Unknown | Efficacy of Iodine Complex Against COVID-19 Patients NCT04473261 | Sohaib Ashraf | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 NCT04450004 | Medicago | Phase 1 |
| Completed | SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding NCT04478019 | University of Wisconsin, Madison | EARLY_Phase 1 |
| Withdrawn | Sirolimus in COVID-19 Phase 1 NCT04371640 | Walter K. Kraft | Phase 1 |
| Completed | COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI) NCT04756518 | East Suffolk and North Essex NHS Foundation Trust | — |
| Completed | Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection NCT04466982 | Cambridge University Hospitals NHS Foundation Trust | — |
| Withdrawn | A Study of Combination Therapies to Treat COVID-19 Infection NCT04459702 | ProgenaBiome | Phase 2 |
| Unknown | Post COVID-19 Functional Status in Egypt NCT04479293 | Assiut University | — |
| Completed | Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU NCT04476914 | University of Colorado, Denver | — |
| Completed | COVID-19 (SARS-CoV-2) in Urine and Semen NCT04446169 | University of Florence | — |
| Completed | Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19 NCT04414241 | Universidad Peruana Cayetano Heredia | Phase 3 |
| Withdrawn | RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM NCT04433078 | Temple University | Phase 2 |
| Completed | Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVI NCT04568863 | Pharmamel S.L. | Phase 2 |
| Withdrawn | Lung Irradiation for COVID-19 Pneumonia NCT04393948 | Brigham and Women's Hospital | N/A |
| Completed | Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) NCT04402970 | University of Missouri-Columbia | Phase 3 |
| Completed | International SARS-CoV-2 (COVID-19) Infection Observational Study NCT04385251 | University of Minnesota | — |
| Unknown | PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort NCT04444609 | Imperial College London | — |
| Completed | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVI NCT04449276 | CureVac | Phase 1 |
| Completed | EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19 NCT04364711 | UMC Utrecht | — |
| Terminated | Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults NCT04445389 | Genexine, Inc. | Phase 1 / Phase 2 |
| Unknown | Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19 NCT04444596 | Medical University Innsbruck | N/A |
| Completed | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) NCT04405739 | Ridgeback Biotherapeutics, LP | Phase 2 |
| Completed | COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School NCT04448717 | University of Zurich | — |
| Unknown | Tomographic Findings in COVID-19 and Influenza NCT04497311 | Universidad de Guanajuato | — |
| Unknown | COVID19 Clinical Predictors and Outcome NCT04416347 | St George's University Hospitals NHS Foundation Trust | — |
| Terminated | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) NCT04397692 | Beyond Air Inc. | N/A |
| Terminated | Tannin Specific Natural Extract for COVID-19 Infection NCT04403646 | Hospital de Clinicas José de San Martín | N/A |
| Completed | Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries A NCT04472078 | Hospital Italiano de Buenos Aires | — |
| Terminated | GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) NCT04408183 | GeneOne Life Science, Inc. | Phase 2 |
| Completed | Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic NCT04400877 | University Hospital, Linkoeping | — |
| Unknown | Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19) NCT04425759 | Hospital de Mataró | — |
| Unknown | QuadraMune(TM) for Prevention of COVID-19 NCT04421391 | Therapeutic Solutions International | N/A |
| Completed | EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19 NCT04396353 | University of Sao Paulo General Hospital | — |
| Completed | SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir) NCT04365595 | University of Zurich | — |
| Completed | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications NCT04373460 | Johns Hopkins University | Phase 2 |
| Completed | Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients NCT04560413 | Fatih Sultan Mehmet Training and Research Hospital | — |
| Unknown | Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) NCT04391101 | Hospital San Vicente Fundación | Phase 3 |
| Completed | Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo NCT04408014 | Butantan Institute | — |
| Unknown | Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Sever NCT04622865 | AB Science | Phase 2 |
| Unknown | Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant NCT05075928 | University Hospital, Strasbourg, France | — |
| Unknown | Somerset and South Essex Coronavirus Antigen Testing NCT04403906 | Somerset NHS Foundation Trust | N/A |
| Completed | Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA NCT04413955 | Children's Hospital Medical Center, Cincinnati | — |
| Unknown | Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers NCT04387890 | Hospital Italiano de Buenos Aires | — |
| Unknown | The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Stud NCT04391400 | Invivoscribe, Inc. | — |
| Completed | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vacci NCT04405076 | ModernaTX, Inc. | Phase 2 |
| Unknown | Vienna Versus SARS-CoV-2 Virus Study NCT04407429 | Medical University of Vienna | — |
| Unknown | Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19 NCT04405492 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Cardiac COVID-19 Health Care Workers NCT04413071 | AORTICA Group | — |
| Unknown | Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19 NCT04406233 | University of Sao Paulo | — |
| Terminated | Azithromycin for COVID-19 Treatment in Outpatients Nationwide NCT04332107 | Thomas M. Lietman | Phase 3 |
| Completed | Nigella Sativa in COVID-19 NCT04401202 | King Abdulaziz University | Phase 2 |
| Unknown | CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 NCT04356482 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Phase 1 / Phase 2 |
| Completed | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-infla NCT04492514 | Kristin Hudock | Phase 2 |
| Completed | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-infla NCT04399980 | The Cleveland Clinic | Phase 2 |